Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Takayasu Arteritis
Study data from Georgetown University provide new insights into takayasu arteritis
July 27th, 2009
According to a study from the United States, "Interim outcome of endovascular management of Takayasu arteritis (TA) was determined retrospectively to assess the efficacy of angioplasty and/or stenting in 24 patients with 35 lesions in the chronic inactive stage. The renal (n = 16), subclavian/innominate (n = 11), and carotid (n = 5) arteries and abdominal aorta (n = 3) were treated." "Twenty-six lesions achieved excellent to good target lesion revascularization with no residual or only minimal residual stenosis, whereas five had a moderate result. Thirty lesions achieved satisfactory hemodynamic correction. Restenosis was observed in 8 lesions treated with angioplasty...
Source: Biotech Business Week (2009-07-27)
|
